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We characterized 44 Salmonella enterica serotype 
Typhimurium isolates from Tongji Hospital outpatients in 
Wuhan, China, May 2002–October 2005. All 31 ciproﬂ  ox-
acin-resistant isolates were also resistant to >8 other an-
timicrobial drugs and carried >2 mutations in GyrA and 1 
mutation in ParC. Class 1 integrons were identiﬁ  ed in 37 
isolates.
S
almonellae are a common cause of community-acquired 
foodborne bacterial gastroenteritis worldwide. The in-
cidence of Salmonella infections in the People’s Republic 
of China has not been well documented. However, in the 
United States, ≈1.4 million persons are infected by Salmo-
nella spp. each year (1). Although >2,500 serotypes have 
been reported, Salmonella enterica serotype Typhimurium 
is 1 of the leading serotypes causing salmonellosis world-
wide (2). Fluoroquinolones such as ciproﬂ  oxacin are strong-
ly recommended for treatment of severe S. Typhimurium 
infections in adults (3). 
In this study, we characterized all S. Typhimurium iso-
lates recovered from May 2002 through October 2005 from 
outpatients of Tongji Hospital, Wuhan, China, a sentinel 
hospital in the National Center for Surveillance of Antimi-
crobial Resistance. During the time of this study, Tongji 
Hospital strictly followed the recommendation for treat-
ment of severe S. Typhimurium infections.
The Study
We analyzed stool samples from outpatients who came 
to Tongji Hospital from the local community for treatment 
of diarrhea during the study period. A total of 44 S. Ty-
phimurium isolates were recovered from the samples. S. 
Typhimurium was identiﬁ  ed by using standard biochemical 
tests and commercial typing antiserum (Statens Serum In-
stitute, Copenhagen, Denmark) according to the manufac-
turer’s instructions. MICs of 15 antimicrobial drugs (Table) 
were determined by using the broth-microdilution method; 
susceptibility to streptomycin was measured by using the 
disk-diffusion method as recommended by the Clinical and 
Laboratory Standards Institute (4). All isolates were further 
characterized by mutation analysis in the quinolone-resis-
tance determining regions (QRDRs), pulsed-ﬁ  eld gel elec-
trophoresis (PFGE), and screening for class I integrons and 
β-lactamase genes as previously described (5–8).
Of the 44 isolates, 36 (82%) were resistant to nalidixic 
acid and 31 (70%) were resistant to ciproﬂ  oxacin (Table). 
Only 3 isolates, recovered in 2002, were susceptible to all 
15 tested antimicrobial drugs; 36 (82%) displayed resis-
tance to at least 8 drugs. Of 13 antimicrobial drug–resis-
tant phenotypes identiﬁ  ed, the most often observed phe-
notype (21/44) was resistance to amoxicillin–clavulanic 
acid, ampicillin, chloramphenicol, ciproﬂ  oxacin,  genta-
micin, nalidixic acid, sulfamethoxazole, streptomycin, 
trimethoprim–sulfamethoxazole, and tetracycline (R-type 
AcAmCCpGNSStSxtT). All isolates were susceptible to 
cefotaxime and ceftazidime; 5 isolates obtained in 2004 
were intermediately susceptible to cefepime (MIC 16 μg/
mL) (online Appendix Figure, available from www.cdc.
gov/EID/content/14/3/493-appG.htm).
Overall, 8 PFGE strain types (A–H) and 6 clusters 
(1–6) were identiﬁ  ed. All isolates that belonged to clusters 
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Table. Resistance phenotypes of Salmonella enterica serotype 
Typhimurium isolated from Tongji Hospital outpatients, Wuhan, 
China, May 2002–October 2005
Antimicrobial agent 
MIC,
Pg/mL*
No. resistant 
isolates
(n = 44) 
Phenicols (chloramphenicol)  !32 33
Penicillins 
 Ampicillin  !32 35
 Amoxicillin–clavulanic  acid  !32/16 32
Cephalosporins
 Cefepime  !32 0
 Cefotaxime  !64 0
 Ceftriaxone  !64 0
Tetracyclines (tetracycline) !16 36
Aminoglycosides 
 Amikacin  !64 2
 Gentamicin  !16 35
 Kanamycin  !64 15
 Streptomycin†  NA 40
Sulfonamides and potentiated sulfonamides 
 Sulfamethoxazole  !512 39
 Trimethoprim-sulfamethoxazole  !4/76 36
Quinolones and fluoroquinolones 
 Nalidixic  acid  !32 36
 Ciprofloxacin  !4 31
*MICs were determined by the broth-microdilution method; results were 
interpreted in accordance with the interpretive standards of the Clinical 
and Laboratory Standards Institute (4).
†Resistance to streptomycin was determined by disk-diffusion method.  
NA, not applied. 1, 2, and 4 were resistant to ciproﬂ  oxacin and to 8–11 other 
antimicrobial drugs. Two dominant patterns, B and F, were 
identiﬁ  ed and included 16 and 10 ciproﬂ  oxacin-resistant 
isolates, respectively. Among 16 isolates of pattern B, 14 
isolates showed the R-type AcAmCCpGNSStSxtT, and 
1 was additionally resistant to kanamycin. In pattern F, 4 
isolates showed the R-type AcAmCCpGNSStSxtT, and 5 
were additionally resistant to kanamycin.
Point mutations in the QRDR of gyrA, parC, or parE 
were identiﬁ  ed in 35 of 36 nalidixic acid–resistant isolates, 
whereas no gyrB mutations and no qnr plasmid were found. 
For 5 nalidixic acid–resistant and ciproﬂ  oxacin low-level–
resistant isolates, 4 isolates harbored single (D87N) or dou-
ble (S83F, D87N) mutations in GyrA, and no mutation was 
found in 1 isolate (ST6). All 31 ciproﬂ  oxacin-resistant iso-
lates accumulated a minimum of 3 mutations: GyrA(S83F, 
D87N), ParC(S80R) (28 isolates) or GyrA(S83F, D87G), 
ParC(S80R) (3 isolates). Two ciproﬂ  oxacin-resistant iso-
lates with PFGE pattern C and 1 isolate with PFGE pattern 
A2 harbored an additional mutation in ParE (S458P) (on-
line Appendix Figure).
Of 39 sulfamethoxazole-resistant isolates encompass-
ing PFGE clusters 1, 2, 3, and 4, 37 possessed class 1 inte-
grons. All class 1 integron–positive isolates were resistant 
to 6–12 antimicrobial drugs; 2 distinct class 1 integrons 
were identiﬁ  ed in 37 isolates. Of isolates obtained from 
2002 through 2005, 32 contained a 1.9-kb integron gene 
cassette dhfrXII-orfF-aadA2. In 2004 and 2005, 3 and 2 
isolates, respectively, contained a 2-kb integron gene cas-
sette blaOXA-30-aadA1. None of the 36 ampicillin-resistant 
isolates contained TEM or SHV enzyme, but OXA-30 gene 
was detected in 32 isolates, identical in DNA sequence to 
GenBank AF255921. All 32 isolates harboring OXA-30 
enzyme showed MICs to cefepime of 2–16 μg/mL, where-
as isolates lacking OXA-30 showed MICs to cefepime of 
<1 μg/mL. In 2004, 5 isolates harboring OXA-30 enzyme 
with PFGE pattern F showed intermediate susceptibility to 
cefepime. All ciproﬂ  oxacin-resistant S. Typhimurium iso-
lates also harbored class 1 integron, β-lactamases, and were 
phenotypically resistant to 8–11 additional antimicrobial 
drugs (online Appendix Figure).
Conclusions
We report a high incidence of ﬂ  uoroquinolone-resistant 
S. Typhimurium isolates from Tongji Hospital outpatients. 
The MIC variation for ciproﬂ  oxacin differed 2- to 4-fold in 
isolates that had the same QRDR mutation proﬁ  le, which 
implies that other mechanisms might partially contribute 
to the resistance phenotype (online Appendix Figure). Af-
ter PFGE analysis, S. Typhimurium isolates were grouped 
into 3 ciproﬂ  oxacin-susceptible clusters and ciproﬂ  oxacin-
resistant clusters. Similar distribution patterns have also 
been observed in isolates from Japan (9), which suggests a 
distinct genetic lineage for ciproﬂ  oxacin-resistant isolates 
that have become dominant. Studies have reported that cip-
roﬂ  oxacin-resistant S. Typhimurium isolates were usually 
resistant to multiple drugs (9,10). In this study, all cipro-
ﬂ  oxacin-resistant S. Typhimurium isolates were resistant to 
8–11 additional antimicrobial drugs. Among the 32 isolates 
harboring OXA-30 enzyme in this study, only 5 with PFGE 
pattern F showed intermediate resistance to cefepime, 
which suggests different levels of OXA gene expression or 
the contribution of other unknown mechanisms.
The high incidence of quinonlone-resistant S. Ty-
phimurium isolates in this study might be affected by 
several factors. First, patients infected by antimicrobial 
drug–resistant S. Typhimurium strains had higher rates of 
hospitalization than did patients infected by susceptible 
strains (11,12), and the isolates in this study were from a 
university-afﬁ  liated medical center that usually treats pa-
tients with severe illness. Second, US studies have estimat-
ed that half of outpatient antimicrobial drugs were inap-
propriately prescribed for conditions such as viral illness 
(13). In China, inappropriate prescriptions might be even 
more common because antimicrobial drug prescriptions in 
hospitals are a source of proﬁ  t. Although we do not have 
patient antimicrobial drug–use information, the easy ac-
cess to antimicrobial drugs raises the possibility that out-
patients might have taken ﬂ  uoroquinolones after the onset 
of the illness but before the collection of stool specimens. 
Third, because livestock products are a common source of 
salmonellosis, the dissemination of ciproﬂ  oxacin-resistant 
S. Typhimurium might have been facilitated by the use of 
ﬂ  uoroquinolones in livestock production (2). Last, use of 
other antimicrobial drugs, such as ampicillin, gentamicin, 
or streptomycin, may also contribute to the spreading of 
ﬂ  uoroquinolone-resistant S. Typhimurium because all the 
ciproﬂ  oxacin-resistant isolates were also resistant to 8–11 
additional antimicrobial drugs.
Although  ﬂ   uoroquinolone-resistant isolates were 
prevalent in Tongji Hospital, ciproﬂ  oxacin is still empiri-
cally used to treat salmonellosis in adults, due partly to the 
absence of systematic surveillance programs to actively 
monitor antimicrobial drug resistance in Salmonella spp. 
Because local data on antimicrobial drug susceptibility are 
less available, we strongly recommend that hospitals and 
national and local health laboratories develop and maintain 
the capacity to perform Salmonella culture and in vitro sus-
ceptibility testing.
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